Top

Global Glioblastoma Multiforme Therapeutics Market 2015-2019

Category : Diagnostic and Biotech  | Published Date : Jul-2015 | Pages : 81
enquire GET DISCOUNT
About Glioblastoma Multiforme
Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor. 
Glioblastoma multiforme is the most common variant of brain tumor, and highly invasive in nature. It may turn up in the cerebrum, mostly in the frontal and temporal lobes, and seldom spreads in areas outside the brain. The tumor progresses rapidly, and is among the most difficult-to-treat cancer with limited treatment options. 
Glioblastoma multiforme is also known as Class IV astrocytoma which has an unknown etiology, and is more frequent in men than women. Some of the common symptoms of glioblastoma multiforme are increased intracranial pressure resulting in nausea, vomiting, and headache, cognitive and visual impairment, motor dysfunction, seizures, loss in sensory functions, and changes in personality, mood or concentration. The condition can be broadly classified into two types, primary or de novo glioblastoma multiforme (which progresses very fast) and secondary glioblastoma multiforme (which is known to progress at a slower rate). Glioblastoma multiforme can be treated by chemotherapy, steroids, radiation therapy, proton therapy, surgical procedure, and immunotherapies, which are the emerging treatment options yet to hit the market. 
Technavio analysts forecast the global glioblastoma multiforme therapeutics market to grow at a CAGR of 11.94 percent during 2014-2019.
Covered in this Report
The report covers the present scenario and the growth prospects of the global glioblastoma multiforme therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various off-label and branded drugs and the expected launch of vaccines and drug candidates used in the treatment of glioblastoma multiforme. 
Based on the route of administration of the drugs used to treat glioblastoma multiforme, the market is segmented as follows:
• Oral
• Parenteral 
Based on the type of molecules of the drugs used to treat glioblastoma multiforme, the market is segmented as follows:
• Small Molecules
• Biologics
This report includes a discussion on the market in the following three regions: 
• The Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
• EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle Eastern and African countries, such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
• APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India
Technavio also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, we discuss the major drivers influencing market growth and also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.
The Technavio report, namely Global Glioblastoma Multiforme Therapeutics Market 2015-2019, is based on an in-depth market analysis, with inputs from industry experts. The report covers the Americas, and EMEA and APAC markets. It presents the market landscape and its growth prospects in the coming years.
Key Regions
• Americas 
• EMEA        
• APAC
Key Vendors
• Arbor Pharmaceuticals
• Bristol-Myers Squibb
• Eisai
• F. Hoffmann-La Roche
• Merck  
Other Prominent Vendors
 
• AB Science
• Abbvie
• Actelion
• Activartis Biotech
• Advantagene
• Agenus
• Agios
• Amgen
• Angiochem
• Apogenix
• Axelar
• BioNTech
• Boehringer Ingelheim
• Boston Biomedical
• Bristol-Myers Squibb
• Celgene
• Celldex Therapeutics
• ChemoCentryx
• Cortice Biosciences
• CytoVac
• CytRx
• Deciphera 
• Del Mar Pharmaceuticals
• Diffusion Pharmaceuticals 
• DNATrix
• Eli Lilly
• Epitopoietic Research 
• e-Therapeutics
• Exelixis
• G W Pharmaceuticals
• Genspera
• immatics  
• ImmunoCellular Therapeutics
• Immunovaccine
• Intrexon
• IRAD Oncology
• Karyopharm Therapeutics
• Kite Pharma
• Life Science Pharmaceuticals
• Medicenna Therapeutics
• Merck
• Merrimack Pharmaceuticals
• Nektar Therapeutics
• Northwest Biotherapeutics 
• Novartis
• Noxxon
• OncoSynergy
• Oncovir
• Ono Pharmaceutical
• Peregrine Pharmaceuticals
• Plexxikon
• Sanofi
• Seattle Genetics
• Spectrum Pharmaceuticals
• Stemline Therapeutics
• Tocagen
• Tracon Pharma
• TVAX Biomedical
• VBL Therapeutics
• Virttu Biologics 
• Ziopharm Oncology
Market Driver
• Lack of Treatment Options for Glioblastoma Multiforme
• For a full and detailed list, view our report
Market Challenge
• Use of Off-label Drugs
• For a full and detailed list, view our report
Market Trend
• Prospective Entry of Novel Agents
• For a full and detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Global Glioblastoma Multiforme Therapeutics Market
06.1.1 Market Overview
06.1.2 Market Size and Forecast
06.2 Five Forces Analysis
07. Market Segmentation by Route of Administration
07.1 Oral
07.2 Parenteral
08. Market Segmentation by Type of Molecule
08.1 Small Molecules
08.2 Biologics
09. Geographical Segmentation
09.1 Glioblastoma Multiforme Therapeutics Market in Americas
09.1.1 Market Overview
09.1.2 Market Size and Forecast
09.2 Glioblastoma Multiforme Therapeutics Market in EMEA
09.2.1 Market Overview
09.2.2 Market Size and Forecast
09.3 Glioblastoma Multiforme Therapeutics Market in APAC
09.3.1 Market Overview
09.3.2 Market Size and Forecast
10. Buying Criteria
11. Pipeline Portfolio
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 Arbor Pharmaceuticals
18.2.2 Bristol-Myers Squibb
18.2.3 Eisai
18.2.4 F. Hoffmann-La Roche
18.2.5 Merck
18.3 Other and Possible Future Prominent Vendors
19. Key Vendor Analysis
19.1 Arbor Pharmaceuticals
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Strategy
19.1.4 Recent Developments
19.1.5 SWOT Analysis
19.2 Bristol-Myers Squibb
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Key Product Offerings
19.2.4 Revenue by Geography
19.2.5 Business Strategy
19.2.6 Key Information
19.2.7 SWOT Analysis
19.3 Eisai
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Comparison between Revenue, Operating Income, and Net Income
19.3.4 Sales by Geography
19.3.5 Business Strategy
19.3.6 Key Information
19.3.7 SWOT Analysis
19.4 F. Hoffmann-La Roche
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation
19.4.4 Business Segmentation by Revenue 2012 and 2013
19.4.5 Sales by Geography
19.4.6 Business Strategy
19.4.7 Key Information
19.4.8 SWOT Analysis
19.5 Merck
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation by Revenue 2013
19.5.4 Business Segmentation by Revenue 2012 and 2013
19.5.5 Sales by Geography
19.5.6 Business Strategy
19.5.7 Key Developments
19.5.8 SWOT Analysis
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Snapshot of the Global Glioblastoma Multiforme Therapeutics Market
Exhibit 3: Global Glioblastoma Multiforme Therapeutics Market 2014-2019 ($ millions)
Exhibit 4: Key Takeaways: Global Glioblastoma Multiforme Therapeutics Market
Exhibit 5: Segmentation of Global Glioblastoma Multiforme Therapeutics Market by Route of Administration
Exhibit 6: Segmentation of Global Glioblastoma Multiforme Therapeutics Market by Type of Molecule
Exhibit 7: Segmentation of Global Glioblastoma Multiforme Therapeutics Market by Geography 2014
Exhibit 8: Glioblastoma Multiforme Therapeutics Market in Americas 2014-2019 ($ millions)
Exhibit 9: Glioblastoma Multiforme Therapeutics Market in EMEA 2014-2019 ($ millions)
Exhibit 10: Glioblastoma Multiforme Therapeutics Market in APAC 2014-2019 ($ millions)
Exhibit 11: Global Glioblastoma Multiforme Therapeutics Market by Geography 2014-2019
Exhibit 12: Glioblastoma Multiforme: Pipeline Portfolio
Exhibit 13: Drug Candidates by Stage of Development (percentage)
Exhibit 14: Drivers of the Global Glioblastoma Multiforme Therapeutics Market
Exhibit 15: Challenges of the Global Glioblastoma Multiforme Therapeutics Market
Exhibit 16: Trends in the Global Glioblastoma Multiforme Therapeutics Market
Exhibit 17: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 18: Bristol-Myers Squibb Co.: Geographical Segmentation by Revenue 2013
Exhibit 19: Eisai: Comparison between Revenue, Operating Income, and Net Income 2011-2013 ($ billions)
Exhibit 20: Eisai: Sales by Geography 2013 ($ billions)
Exhibit 21: F. Hoffmann-La Roche: Business Segmentation2013
Exhibit 22: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 23: F. Hoffmann-La Roche: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 24: F. Hoffmann-La Roche: Sales by Geography 2013 (Diagnostics Division)
Exhibit 25: Merck: Business Segmentation by Revenue 2013
Exhibit 26: Merck: Business Segmentation by Revenue 2012 and 2013 ($ billions)
Exhibit 27: Merck: Sales by Geography 2013
...
Publisher Name : Technavio

SIMILAR MARKET STUDIES

Please Select Format
Single User: US $ 2500
Five User: US $ 3000
Site User: US $ 4000
Global User: US $ 10000

NEED MORE INFORMATION
Contact us
Call us +1-971-202-1575
--- or ---
help@bigmarketresearch.com
WHY BIG MARKET RESEARCH
With high quality and penned to perfection, Big Market Research is an exclusive online market to get best market research reports for your business needs and strategies. We recommend you to stop browsing as soon as you discover our website. This is because we firmly believe that once you reach here; all your business concerns will be addressed.

We have a huge collection of market research report from numerous filed which will provide you with all the necessary solution. We make sure that reports that we sell are true in context, have a quality that is unrivaled, fully integrated with equal spread of opinion. They will give you proper insights into different opportunities one may locate for their start-up pr expansion.

Let your qualms and concern be sidelined through our high end syndicated as well as customized reports.
Top